scispace - formally typeset
Open AccessJournal ArticleDOI

FSH Levels Predict Bone Loss in Premenopausal Women Treated for Breast Cancer More Than One Year After Treatment

Reads0
Chats0
TLDR
Among premenopausal women with breast cancer treated with chemotherapy, baseline FSH levels are strongly associated with subsequent bone loss and further studies are needed to establish the optimal timing of FSH measurement in relation to breast cancer treatment.
Abstract
Context: Biomarkers to predict bone loss in premenopausal women after breast cancer treatment have not been examined. Objective: To determine whether baseline FSH predicts subsequent bone loss. Design: Secondary data analysis of the Exercise for Bone Health: Young Breast Cancer Survivors study, in which women were randomized to a 12-month exercise program or monthly health newsletter. Setting: Community dwelling women. Participants: A total of 206 women age less than or equal to 55 years at breast cancer diagnosis who had received adjuvant chemotherapy and were at least 1 year after diagnosis. Intervention: Serum collected at baseline (an average of 302 ± 148 d after completing chemotherapy) was analyzed for FSH. Main Outcome Measure: Change in bone mineral density. Results: In linear regression models, baseline FSH levels predicted bone loss over the ensuing 12 months at the lumbar spine and femoral neck including after adjustment for age, ethnicity, treatment group (exercise vs control), baseline bone d...

read more

Citations
More filters
Journal ArticleDOI

Estrogen Receptor β as a Pharmaceutical Target

TL;DR: Here, this work focuses on estrogen receptor (ER)β, which has promise as a selective target in hormone replacement therapy, and in breast and prostate cancers.
Journal ArticleDOI

In Vivo and In Vitro Impact of Carbohydrate Variation on Human Follicle-Stimulating Hormone Function.

TL;DR: An integrated approach involving genetic models, in vitro signaling studies, FSH biochemistry, relevance of physiological changes in FSH glycoform abundance, and the impact of FSH macroheterogeneity on fertility and reproductive aging is described.
Journal ArticleDOI

The Relationship between Follicle-stimulating Hormone and Bone Health: Alternative Explanation for Bone Loss beyond Oestrogen?

TL;DR: FSH may have a direct action on bone health independent of oestrogen by enhancing bone resorption and its effects may be attenuated in the presence of overt sex hormone deficiency.
Journal ArticleDOI

Bone mineral density is compromised in very long-term survivors of irradiated childhood brain tumor.

TL;DR: Evaluating the current bone health by measuring the bone mineral density (BMD) in irradiated, adult long-term survivors of childhood brain tumors found low BMD should be taken in consideration in treatment of irradiated childhood brain tumor survivors especially in those with previous fractures in long bones.
Journal ArticleDOI

Modulation of Gonadotropins Activity by Antibodies.

TL;DR: Antibodies are powerful tools that were largely used to decipher gonadotropins' actions and they have shown their utility as therapeutics in several other indications such as cancer.
References
More filters
Book ChapterDOI

Breast Cancer Statistics

TL;DR: Breast cancer rates vary largely by race/ethnicity and socioeconomic status (SES), and geographic region, and death rates are higher in African American women than in whites, despite their lower incidence rates.
Journal ArticleDOI

Breast cancer statistics, 2013

TL;DR: An overview of female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening is provided, with African American women having the poorest breast cancer survival of any racial/ethnic group.
Journal ArticleDOI

Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer

TL;DR: In postmenopausal women, treatment with tamoxifen is associated with preservation of the bone mineral density of the lumbar spine, and whether this favorable effect on bone mineraldensity is accompanied by a decrease in the risk of fractures remains to be determined.
Journal ArticleDOI

Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.

TL;DR: Ovarian damage is the most significant long-term sequela of adjuvant chemotherapy in premenopausal breast cancer survivors and a common definition of the following important terms is suggested: menopausal status, CRA (early and late), temporary CRA, and oligomenorrhea in the setting of adjUvant treatment.
Related Papers (5)